FT-516 is a cell therapy commercialized by Fate Therapeutics, with a leading Phase I program in Marginal Zone B-cell Lymphoma. According to Globaldata, it is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of FT-516’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for FT-516 is expected to reach an annual total of $61 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

FT-516 Overview

FT-516 is under development for the treatment of hematologic malignancies including relapsed or refractory B cell lymphoma, relapsed or refractory acute myeloid leukemia, relapsed/refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), indolent non-Hodgkin lymphoma (iNHL), aggressive B-cell lymphoma transformed from iNH (transformed iNHL), follicular lymphoma, marginal zone B-cell Lymphoma and coronavirus disease 2019 (COVID-19) in hospitalized patients with hypoxia. The therapeutic candidate constitutes induced pluripotent stem cell (iPSC)-derived NK cells expressing a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor. It is developed based on iPSC technology- off-the-shelf using renewable engineered pluripotent cell lines.

FT-516 was under development for the treatment of solid tumors including ovarian cancer, epithelial ovarian cancer, fallopian tube, primary peritoneal cancer, melanoma, non-small cell lung cancer, triple-negative breast cancer.

Fate Therapeutics Overview

Fate Therapeutics is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. Its pipeline also includes a donor-derived cell product candidate for the treatment of hematological malignancies. Fate uses its proprietary human-induced pluripotent stem cell (iPSC) platform for product development. The company also has research collaborations with companies, academic centers, and medical centers for the advancement of products and technologies. Fate Therapeutics is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$55.9 million for the fiscal year ended December 2021 (FY2021), an increase of 77.7% over FY2020. The operating loss of the company was US$217 million in FY2021, compared to an operating loss of US$128.1 million in FY2020. The net loss of the company was US$212.2 million in FY2021, compared to a net loss of US$173.4 million in FY2020. The company reported revenues of US$15 million for the third quarter ended September 2022, a decrease of 19.2% over the previous quarter.

For a complete picture of FT-516’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.